Advertisement
CERS vs DHR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CERS is a Hold and DHR is a Hold.
CERS's RSI Indicator recovers from oversold territory
The RSI Indicator for CERS moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In 22 of the 28 cases the stock moved higher. This puts the odds of a move higher at 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on CERS as a result. In 78 of 103 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for CERS just turned positive on October 20, 2026. Looking at past instances where CERS's MACD turned positive, the stock continued to rise in 32 of 44 cases over the following month. The odds of a continued upward trend are 73%.
Following a +7.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where CERS advanced for three days, in 170 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CERS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
CERS broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CERS entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.878) is normal, around the industry mean (2.923). P/E Ratio (-79.667) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (2.219) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. CERS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CERS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
DHR's Stochastic Oscillator drives into overbought zone
The Stochastic Oscillator for DHR moved into overbought territory on October 21, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for DHR moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 12 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 41%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DHR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.
DHR broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on DHR as a result. In 57 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
The Moving Average Convergence Divergence (MACD) for DHR just turned positive on October 14, 2026. Looking at past instances where DHR's MACD turned positive, the stock continued to rise in 27 of 47 cases over the following month. The odds of a continued upward trend are 57%.
Following a +3.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where DHR advanced for three days, in 174 of 319 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.
The Aroon Indicator entered an Uptrend today. In 111 of 199 cases where DHR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 16 (best 1 - 100 worst), indicating outstanding price growth. DHR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.127) is normal, around the industry mean (64.450). P/E Ratio (41.465) is within average values for comparable stocks, (2.086). Projected Growth (PEG Ratio) (1.361) is also within normal values, averaging (3.473). Dividend Yield (0.007) settles around the average of (0.002) among similar stocks. P/S Ratio (5.900) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 53 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 77 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DHR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
CERS | DHR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 31 | 37 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 18 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 94 | 77 | |
PRICE GROWTH RATING 1..100 | 57 | 16 | |
P/E GROWTH RATING 1..100 | 19 | 53 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CERS's Valuation (8) in the Medical Specialties industry is in the same range as DHR (18). This means that CERS’s stock grew similarly to DHR’s over the last 12 months.
CERS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as DHR (100). This means that CERS’s stock grew similarly to DHR’s over the last 12 months.
DHR's SMR Rating (77) in the Medical Specialties industry is in the same range as CERS (94). This means that DHR’s stock grew similarly to CERS’s over the last 12 months.
DHR's Price Growth Rating (16) in the Medical Specialties industry is somewhat better than the same rating for CERS (57). This means that DHR’s stock grew somewhat faster than CERS’s over the last 12 months.
CERS's P/E Growth Rating (19) in the Medical Specialties industry is somewhat better than the same rating for DHR (53). This means that CERS’s stock grew somewhat faster than DHR’s over the last 12 months.
| CERS | DHR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 79% | 2 days ago 41% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 65% |
| Momentum ODDS (%) | 2 days ago 76% | 2 days ago 64% |
| MACD ODDS (%) | 2 days ago 73% | 2 days ago 57% |
| TrendWeek ODDS (%) | 2 days ago 78% | 2 days ago 57% |
| TrendMonth ODDS (%) | 2 days ago 82% | 2 days ago 57% |
| Advances ODDS (%) | 2 days ago 75% | 8 days ago 55% |
| Declines ODDS (%) | 15 days ago 83% | 3 days ago 59% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 55% |
| Aroon ODDS (%) | 2 days ago 85% | 2 days ago 56% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CERS’s FA Score shows that 2 FA rating(s) are green while DHR’s FA Score has 2 green FA rating(s).
- CERS’s FA Score: 2 green, 3 red.
- DHR’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CERS’s TA Score shows that 4 TA indicator(s) are bullish while DHR’s TA Score has 4 bullish TA indicator(s).
- CERS’s TA Score: 4 bullish, 4 bearish.
- DHR’s TA Score: 4 bullish, 4 bearish.
Price Growth
CERS (@Medical/Nursing Services) experienced а +6.70% price change this week, while DHR (@Medical Specialties) price change was +4.08% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.58%. For the same industry, the average monthly price growth was -10.79%, and the average quarterly price growth was -10.51%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.66%. For the same industry, the average monthly price growth was -7.04%, and the average quarterly price growth was +41.88%.
Reported Earning Dates
CERS is expected to report earnings on Nov 02, 2026.
DHR is expected to report earnings on Feb 03, 2027.
Industries' Descriptions
@Medical/Nursing Services (-1.58% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-3.66% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
CERS and
Correlation & Price change
A.I.dvisor indicates that over the last year, CERS has been loosely correlated with ICUI. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CERS jumps, then ICUI could also see price increases.
| Ticker / NAME | Correlation To CERS | 1D Price Change % | ||
|---|---|---|---|---|
| CERS | 100% | +3.46% | ||
| ICUI - CERS | 46% Loosely correlated | -0.15% | ||
| UTMD - CERS | 45% Loosely correlated | -0.47% | ||
| RVTY - CERS | 44% Loosely correlated | +0.38% | ||
| ATRC - CERS | 43% Loosely correlated | N/A | ||
| DHR - CERS | 43% Loosely correlated | +4.29% | ||
More | ||||